▲❆❇❖❘❆❚❖■❘❊✥❉❊✥❇■❖▲❖●■❊✥▼❊❉■❈❆▲❊

✥✸✻✥❆✈❡♥✉❡✥P❛st❡✉r✱✥❇P✥✷✷✵✥❉❆❑❆❘✥❚❡❧✥✿✥✭✰✷✷✶✮✥✸✸✥✽✸✾✥✾✷✥✸✸✥✴✾✷✥✸✷
❈❡♥tr❡✥♣ré❧è✈❡♠❡♥t✥❱❉◆✥✿✥✭✰✷✷✶✮✥✸✸✥✽✺✾✥✷✽✥✺✶
▼❛✐❧✥✿✥❜✐♦♠❡❞s❡❝❅♣❛st❡✉r✳s♥✥✥■♥t❡r♥❡t✥✿✥✇✇✇✳♣❛st❡✉r✳s♥

❍♦r❛✐r❡s✥❞✬♦✉✈❡rt✉r❡

✥▲✉♥❞✐✲❏❡✉❞✐✥✿✥✼❤✸✵✲✶✽❤✵✵
❱❡♥❞r❡❞✐✥✿✥✼❤✸✵✲✶✸❤✸✵✴✶✺❤✲✶✽❤
❙❛♠❡❞✐✥♠❛t✐♥✥✿✥✼❤✸✵✲✶✶❤✵✵

❈♦❞❡✥✿✥❑❆✥✥✥❆❈◗ Monsieur
Pr❡s❝r✐♣t❡✉r✥✿✥❑❆✥❊▲✥❍❆❉❏■✥❋❆❘❨✥✥✥✥✥✥✥✥✥✥✥✥✥✥ KA Amadou
❆❞r❡ss❡✥✥✥✥✥✥✿✥❍▼❖✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥
✥✥✥✥✥✥❉❆❑❆❘✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥ SCART URBAM
❚❡❧✥✿✥✥✥✥✥✥✥✥✥✥✥✥❋❛①✥✿✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥ DAKAR
❉❛t❡✥❞✉✥♣ré❧è✈❡♠❡♥t✥✿✥✥✼✳✵✾✳✷✵✷✸
❤✵✾✵✼✻✾✾
❉❛t❡✥❞❡✥♥❛✐ss❛♥❝❡✥✥✥✿✥✶✵✳✵✷✳✶✾✻✷✥✲✥s❡①❡✥▼✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥✥
qqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq
DAKAR, le 8 Septembre 2023

✥✥✥✥✥✥✥✥✥✥✥✥❇■❖❈❍■▼■❊✥❙❆◆●❯■◆❊

GLYCEMIE . . . . . . . . . . : 2,21 g/l 12,27 mmol/l

(Hexokinase - Alinity ABBOTT) (0,70-1,05) (3,89-5,83)

HEMOGLOBINE GLYCOSYLEE (HbA1c).: 10,4 %

(HPLC - D10 BioRad)

INTERPRETATION : (ne s’applique pas aux femmes enceintes)

> 8% : Diabète mal équilibré

< 7% : Objectif à atteindre sous traitement
< 6% : Diabète équilibré

CREATININE . . . . . . . . . : 10,2 mg/l 90,2 µmol/l

(Cinétique - Alinity ABBOTT) (7,2-12,5) (63,7-110,6)

A. SECK Ch. MAHOU T.A. DIALLO B. NDIAYE A. DIOP

Page n° 1/ 1
▲❡s✥rés✉❧t❛ts✥✐❞❡♥t✐❢✐és✥♣❛r✥✥✥✥✥✥s♦♥t✥❝♦✉✈❡rts✥♣❛r✥❧✬❛❝❝ré❞✐t❛t✐♦♥✳ version PDF